Free Trial
NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Price, News & Analysis

$3.10
-0.08 (-2.52%)
(As of 05/29/2024 ET)
Today's Range
$3.09
$3.18
50-Day Range
$3.10
$4.63
52-Week Range
$3.09
$6.20
Volume
85,895 shs
Average Volume
90,579 shs
Market Capitalization
$134.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Harvard Bioscience MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.18
Upright™ Environmental Score
News Sentiment
0.53mentions of Harvard Bioscience in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.06 out of 5 stars

Computer And Technology Sector

530th out of 604 stocks

Analytical Instruments Industry

25th out of 29 stocks

HBIO stock logo

About Harvard Bioscience Stock (NASDAQ:HBIO)

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

HBIO Stock Price History

HBIO Stock News Headlines

The humbling of Harvard
See More Headlines
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
5/29/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
391
Year Founded
1901

Profitability

Net Income
$-3,410,000.00
Pretax Margin
-7.72%

Debt

Sales & Book Value

Annual Sales
$112.25 million
Cash Flow
$0.22 per share
Book Value
$1.58 per share

Miscellaneous

Free Float
39,521,000
Market Cap
$134.63 million
Optionable
Optionable
Beta
1.45

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

HBIO Stock Analysis - Frequently Asked Questions

How have HBIO shares performed in 2024?

Harvard Bioscience's stock was trading at $5.35 at the beginning of 2024. Since then, HBIO shares have decreased by 42.1% and is now trading at $3.10.
View the best growth stocks for 2024 here
.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 620,100 shares, a drop of 9.0% from the April 30th total of 681,200 shares. Based on an average trading volume of 95,600 shares, the days-to-cover ratio is presently 6.5 days.
View Harvard Bioscience's Short Interest
.

When is Harvard Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our HBIO earnings forecast
.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) announced its earnings results on Thursday, March, 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.03 by $0.02. The medical instruments supplier had revenue of $28.15 million for the quarter, compared to the consensus estimate of $27.80 million. Harvard Bioscience had a positive trailing twelve-month return on equity of 0.26% and a negative net margin of 8.18%.

What guidance has Harvard Bioscience issued on next quarter's earnings?

Harvard Bioscience updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $112.3 million-$112.3 million, compared to the consensus revenue estimate of $114.9 million.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional investors include AMH Equity Ltd (5.36%), Vanguard Group Inc. (4.96%), Acadian Asset Management LLC (2.31%), Heartland Advisors Inc. (2.05%), Kennedy Capital Management LLC (0.74%) and Archon Capital Management LLC (0.60%). Insiders that own company stock include Alan I Edrick, Bertrand Loy and James W Green.
View institutional ownership trends
.

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Harvard Bioscience have any subsidiaries?
The following companies are subsidiares of Harvard Bioscience: Data Sciences International.
Read More
This page (NASDAQ:HBIO) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners